

Human Gene Therapy, published by Mary Ann Liebert, Inc., will now offer its authors “**Liebert Open Option**,” an open-access model. Authors now have the choice of making their paper free online worldwide, if they wish to do so. The fee for **Liebert Open Option** papers will be \$3,000. Authors may choose this option when they receive page proofs, or any time thereafter.

All papers submitted to *Human Gene Therapy* are published online ahead of print.

Adding **Liebert Open Option** to the already existing online journal and print publication provides the most effective and complete communication of scientific information to the many members of this field all over the world.

“The journal will continue to be available both online and in print. Online and print are read and used differently,” said Mary Ann Liebert, President and CEO. “Both are important. And because we recognize that both print and online make a contribution to the literature and to the field, **any authors who choose to participate in Liebert Open Option will receive a free print subscription to *Human Gene Therapy* for one year.**”

To access instructions for authors, subscription information, view tables of contents, or read a free sample issue, go to www.liebertpub.com/hum

The Editorial Department
Mary Ann Liebert, Inc., publishers
editorial@liebertpub.com